perifosine + bortezomib

**Perifosine + bortezomib** is a combination of perifosine, a synthetic oral alkylphospholipid, and bortezomib, a proteasome inhibitor, investigated for the treatment of relapsed or refractory multiple myeloma. Perifosine inhibits signal transduction pathways including PI3K/Akt, and bortezomib inhibits the 26S proteasome, resulting in apoptosis of cancer cells. The combination showed promising activity and manageable toxicity in early phase studies in heavily pretreated multiple myeloma patients, but a phase 3 trial was discontinued early after interim analysis found no significant improvement in progression-free survival over bortezomib plus dexamethasone alone[1][3][5].